Aeglea Bio Therapeutics (NASDAQ:AGLE) had its price objective upped by Needham & Company LLC to $20.00 in a research note issued to investors on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.

AGLE has been the topic of several other research reports. BMO Capital Markets restated an outperform rating and set a $18.00 price objective on shares of Aeglea Bio Therapeutics in a research report on Wednesday, March 14th. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a buy rating to a hold rating in a research report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $14.50.

How to Become a New Pot Stock Millionaire

NASDAQ AGLE opened at $9.01 on Friday. Aeglea Bio Therapeutics has a 1 year low of $2.81 and a 1 year high of $11.35. The company has a market capitalization of $160.81, a price-to-earnings ratio of -5.01 and a beta of -0.20.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last posted its earnings results on Tuesday, March 13th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter. Aeglea Bio Therapeutics had a negative return on equity of 48.29% and a negative net margin of 523.37%. The firm had revenue of $1.48 million during the quarter. equities analysts anticipate that Aeglea Bio Therapeutics will post -1.93 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in shares of Aeglea Bio Therapeutics by 150.8% during the 4th quarter. Renaissance Technologies LLC now owns 32,100 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 19,300 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Aeglea Bio Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after buying an additional 12,966 shares in the last quarter. Finally, Jennison Associates LLC raised its position in shares of Aeglea Bio Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,393,439 shares of the biotechnology company’s stock valued at $7,539,000 after buying an additional 8,372 shares in the last quarter. Hedge funds and other institutional investors own 47.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2018/04/17/aeglea-bio-therapeutics-agle-price-target-raised-to-20-00-at-needham-company-llc.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.